Combination of Single-Photon Emission Computed Tomography and Magnetic Resonance Imaging to Track 111In-Oxine-Labeled Human Mesenchymal Stem Cells in Neuroblastoma-Bearing Mice Articles uri icon

publication date

  • December 2014

start page

  • 1

end page

  • 10

volume

  • 13

international standard serial number (ISSN)

  • 1535-3508

electronic international standard serial number (EISSN)

  • 1536-0121

abstract

  • URL: http://mi.deckerpublishing.com/index.php/article/combination-of-single-photon-emission-computed-tomography-and-magnetic-resonance-imaging-to-track-111in-oxine-ndash-labeled-human-mesenchymal-stem-cells-in-neuroblastoma-bearing-mice --No tiene DOI -- Abstract: Homing is an inherent, complex, multistep process performed by cells such as human bone marrow mesenchymal stem cells (hMSCs) to travel from a distant location to inflamed or damaged tissue and tumors. This ability of hMSCs has been exploited as a tumor-targeting strategy in cell-based cancer therapy. The purpose of this study was to investigate the applicability of 111In-oxine for tracking hMSCs in vivo by combining single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI). 111In-labeled hMSCs (106 cells) were infused intraperitoneally in neuroblastoma-bearing mice, whereas a control group received a dose of free 111In-oxine. SPECT and MRI studies were performed 24 and 48 hours afterwards. Initially, the images showed similar activity in the abdomen in both controls and hMSC-injected animals. In general, abdominal activity decreases at 48 hours. hMSC-injected animals showed increased uptake in the tumor area at 48 hours, whereas the control group showed a low level of activity at 24 hours, which decreased at 48 hours. In conclusion, tracking 111In-labeled hMSCs combining SPECT and MRI is feasible and may be transferable to clinical research. The multimodal combination is essential to ensure appropriate interpretation of the images.

keywords

  • hematopoietic progenitor cells; in-vivo; myocardial-infarction; cellular-therapy; stromal cells; bone; cancer; in-111; model; spect